Haryana Raxil drug purchase case

Haryana Raxil Drug Purchase Case

The Haryana Raxil Drug Purchase Case refers to a controversial procurement incident that took place in the Indian state of Haryana. This case involves the procurement of Raxil, a fungicide, purportedly used to treat Karnal bunt in wheat. The controversy centers around allegations of irregularities, overpricing, and the lack of necessary approvals for the use of Raxil on wheat crops.

Background

Karnal bunt, caused by the fungus Tilletia indica, is a significant disease affecting wheat crops. It not only reduces the yield but also deteriorates the quality of the wheat. To combat this, the use of fungicides is a common agricultural practice. However, the selection and procurement of such chemicals are subject to regulatory approval and scientific validation.

The Case

In the Haryana Raxil Drug Purchase Case, the state government was accused of buying large quantities of Raxil, manufactured by Bayer CropScience, without following the proper procurement procedures. Critics argued that the purchase was made at inflated prices and without the necessary approval from the Central Insecticides Board & Registration Committee (CIBRC), the central body responsible for the regulation of pesticides in India.

Controversies and Allegations

Several key issues were highlighted in this case:

1. **Lack of Approval**: Raxil (tebuconazole), while effective against certain fungal diseases, was not officially approved by the CIBRC for use against Karnal bunt in wheat at the time of purchase.

2. **Procurement Process**: Allegations surfaced regarding the transparency and fairness of the procurement process. Questions were raised about why the state opted for Raxil when cheaper and approved alternatives were available.

3. **Financial Irregularities**: The financial aspect of the purchase came under scrutiny, with allegations of overpricing. It was suggested that the government paid significantly more for Raxil than its market value.

4. **Impact on Farmers**: There was concern about the potential impact on farmers, including the effectiveness of the fungicide on Karnal bunt and the financial burden placed on them due to the procurement of an expensive, and possibly unnecessary, product.

Investigations and Outcomes

The controversy led to calls for thorough investigations by both governmental and non-governmental organizations. The primary focus was to ascertain the legality and propriety of the procurement process, evaluate the financial transactions, and assess the decision-making process that led to the selection of Raxil.

Public and Political Reaction

The case attracted significant media attention and became a point of contention in Haryana's political landscape. Opposition parties criticized the government's handling of the situation, calling for accountability and transparency. Civil society organizations and farmer unions also expressed their concerns, emphasizing the need for responsible governance and the protection of farmers' interests.

Conclusion

The Haryana Raxil Drug Purchase Case highlights the complexities involved in agricultural procurement, the importance of regulatory approvals, and the need for transparency in government transactions. It serves as a reminder of the challenges in balancing the need for effective agricultural solutions with the principles of fairness, accountability, and value for money.

   This article is a medical stub. You can help WikiMD by expanding it!

Haryana Raxil drug purchase case

• 

  CBI logo

• 

  Bhupinder Singh Hooda in WEF, 2010